Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Metastatic Neuroendocrine Prostate Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, B-Cell 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 38fludarabine 30Rituximab 26obinutuzumab 10Bendamustine Hydrochloride 10fludarabine phosphate 9pembrolizumab 8Specimen Handling 7Etoposide 7venetoclax 6Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6Leukapheresis 6Lenalidomide 6ibrutinib 5Inotuzumab Ozogamicin 5Immunotherapy, Adoptive 5Doxorubicin 5Biopsy 5ublituximab 4tazemetostat 4glofitamab 4Interleukin-2 4Dexamethasone 4Cytarabine 4pomalidomide 3polatuzumab vedotin 3Radiation 3Nivolumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell × Antiemetics × Clear all
NCT03448393 2025-06-04

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
54 enrolled 24 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡